Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Nuvo Research Announces Collaboration to Develop Topical Dermatology Products

Published: Saturday, April 26, 2014
Last Updated: Saturday, April 26, 2014
Bookmark and Share
Company will utilize its proprietary MMPE technology to formulate topical dermatology products.

Nuvo Research Inc. has announced a collaboration involving Ferndale Laboratories, Inc. (Ferndale) and a leading Contract Research Organization (CRO) with significant dermatology experience to develop two topical dermatology products based on Nuvo's patented Multiplexed Molecular Penetration Enhancer (MMPE™) technology.

"This exciting opportunity demonstrates how Nuvo can leverage one of our four proprietary technologies that enhances the delivery of active drugs into or through the skin," said Dan Chicoine, Nuvo's Chairman and Co-CEO. "This agreement validates our patented drug delivery platforms and highlights our ability to expand our development product pipeline through strategic collaborations with partners who will fund the costs of clinical development."

Under the terms of the collaboration agreement, Nuvo will utilize its proprietary MMPE technology to formulate two patented topical dermatology product candidates.

Once the formulations are complete, Ferndale in collaboration with the CRO, will oversee and fund the formulations' advancement through Phase 2 clinical studies. It is anticipated that the product candidates will then be made available for out-licensing.

Licensing revenues, including upfront payments, milestone payments and royalties will be shared by the parties based on a formula that includes compensation to Nuvo for contributing the patented formulations.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Nuvo Research Announces 2013 Fourth Quarter & Year-End Results
Company will commence a Phase 2 study of WF10 with results expected in Q4 2014.
Friday, March 07, 2014
Nuvo Research® and NovaMedica Sign Agreement to Market Pennsaid® in Russia
Sales of Pennsaid 1.5% in Russia to begin in 2015.
Monday, December 23, 2013
Nuvo Research Announces Scientific Presentation at the Annual Meeting of AAI
Data evaluating WF10's therapeutic impact on signs and symptoms of experimentally induced rheumatoid arthritis in mice.
Friday, May 17, 2013
Nuvo Granted U.S. Patent for Using WF10
New derivative formulations for the treatment of Allergic Rhinitis and Allergic Asthma.
Thursday, May 16, 2013
Nuvo Announces Notice of Intention to Grant a European Patent for PENNSAID® 2%
Patent applications currently pending in Australia, Brazil, Canada, China, Hong Kong, India, Israel, Japan and Mexico.
Tuesday, May 14, 2013
Nuvo Research Announces New Listing of Synera® Patent in FDA Orange Book
The Synera Patent expiry date is July 7, 2020.
Thursday, December 27, 2012
Nuvo Research Receives €4.4 Million Additional Funding to Develop WF10
Total cost of the development program is estimated to be €6.3 million.
Thursday, December 27, 2012
Nuvo Research Announces 2012 Second Quarter Results
Company receives notice of a positive opinion for the approval of Pliaglis.
Tuesday, August 07, 2012
Nuvo Research to Receive US$6.0 Million of Milestone Payments from Pliaglis® E.U. Approvals
Nuvo to launch Pliaglis in the E.U. and other territories in the first half of 2013.
Friday, July 20, 2012
Nuvo Research Provides PENNSAID® Commercial Update
U.S. licensee resumes distribution of PENNSAID sample bottles.
Monday, June 18, 2012
Pliaglis Receives Positive Opinion from the BfArM in the E.U.
Enters national licensing phase in 17 E.U. countries.
Tuesday, May 08, 2012
Nuvo Research Announces 2012 First Quarter Results
U.S. prescriptions of Pennsaid continued to grow quarter-over-quarter.
Thursday, May 03, 2012
Nuvo Research Announces Management Change
Stephen L. Lemieux to become Vice President and Chief Financial Officer of Nuvo Research.
Monday, February 13, 2012
Nuvo Research U.S. Awarded US$1.3 Million in Research Grants
The grants were awarded for 2009 and 2010 research programs relating to topical and transdermal formulations.
Thursday, November 11, 2010
Nuvo Research Announces Positive Top-Line WF10 Phase II Trial Results
European Phase II clinical trial evaluating WF10 as a treatment for severe allergic rhinitis meets its primary endpoint.
Tuesday, November 09, 2010
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Grant Supports Project To Develop Simple Test To Screen For Cervical Cancer
UCLA Engineering announces funding from Bill and Melinda Gates Foundation.
Injecting New Life into Old Antibiotics
A new fully synthetic way to make a class of antibiotics called macrolides from simple building blocks is set to open up a new front in the fight against antimicrobial drug resistance.
Insight into Bacterial Resilience and Antibiotic Targets
Variant of CRISPR technology paired with computerized imaging reveals essential gene networks in bacteria.
Advancing Protein Visualization
Cryo-EM methods can determine structures of small proteins bound to potential drug candidates.
Alzheimer’s Protein Serves as Natural Antibiotic
Alzheimer's-associated amyloid plaques may be part of natural process to trap microbes, findings suggest new therapeutic strategies.
Slime Mold Reveals Clues to Immune Cells’ Directional Abilities
Study from UC San Diego identifies a protein involved in the directional ability of a slime mold.
How Do You Kill A Malaria Parasite?
Drexel University scientists have discovered an unusual mechanism for how two new antimalarial drugs operate: They give the parasite’s skin a boost in cholesterol, making it unable to traverse the narrow labyrinths of the human bloodstream. The drugs also seem to trick the parasite into reproducing prematurely.
Illuminating Hidden Gene Regulators
New super-resolution technique visualizes important role of short-lived enzyme clusters.
Supressing Intenstinal Analphylaxis in Peanut Allergy
Study from National Jewish Health shows that blockade of histamine receptors suppresses intestinal anaphylaxis in peanut allergy.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!